Full of money, Pfizer buys Global Blood Therapeutics for $5.4 billion
Aug 8 (Reuters) – Pfizer Inc on Monday agreed to pay $5.4 billion in cash to sickle cell drugmaker Global Blood Therapeutics (GBT.O) as it seeks to capitalize on a surge in revenue from his COVID-19 vaccine and treatment. Pfizer will pay $68.50 per GBT share, representing a 7.3% premium to its Friday closing price … Read more